Huadong pharmaceutical acarbose chewable tablets will be approved as the exclusive dosage form in China

It is worth mentioning that there is no domestic enterprise that has the production approval of acarbose chewable tablets, which will become the exclusive dosage form in China after being approved Acarbose is a new oral hypoglycemic drug There are only three domestic manufacturers of this product, namely Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Bayer pharmaceutical and health care Co., Ltd and Sichuan LVYE Baoguang Pharmaceutical Co., Ltd Among them, the dosage form of lvyebaoguang is capsule and the other two are tablets In addition to Huadong, Hainan Jinrui Pharmaceutical Co., Ltd has applied for the clinical approval of acarbose chewable tablets, which is still early to be listed Guangfa Securities research report pointed out that acarbose is an oral antidiabetic drug with a domestic sales volume of 3 billion yuan Chewable tablet is an exclusive dosage form It can be swallowed immediately before eating or chewed together with the first few mouthfuls of food It is convenient to take and easy to absorb Due to the better competitive structure, higher pricing and better curative effect, chewable tablets are expected to focus on the non base drug market in the future, with a long-term sales scale of 1 billion yuan Huadong medicine is the double leading product in the field of immunity and hypoglycemic medicine in China Acarbose is the second largest core product of the company after bailing capsule.